CB‐012 (NCT06128044) is a gene editing technology from Caribou Biosciences using in‐house Cas12a chRDNA gene editing technology, CLL‐1 (CD371) is expressed on the surface of AML tumor cells and leukemia stem cells, but not on normal HSCs and could be a therapeutic target for AML. The gene discussed is CLEC12A; the disease is neoplasm.